Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
25,400
+150 (0.59%)
Last updated: Apr 1, 2025
Daihan Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 33,759 | 28,426 | 24,961 | 22,670 | 17,381 | Upgrade
|
Depreciation & Amortization | 7,282 | 8,663 | 9,208 | 11,411 | 11,300 | Upgrade
|
Loss (Gain) From Sale of Assets | -58.03 | -22.53 | 9.4 | -41.28 | -19.72 | Upgrade
|
Loss (Gain) From Sale of Investments | -303.6 | -288.69 | - | - | - | Upgrade
|
Provision & Write-off of Bad Debts | 17.05 | 10.8 | -33.29 | -142.8 | -319.09 | Upgrade
|
Other Operating Activities | 2,115 | 4,194 | 2,632 | 7,386 | 8,587 | Upgrade
|
Change in Accounts Receivable | -385.22 | 437.93 | -2,172 | -10.94 | 7,321 | Upgrade
|
Change in Inventory | -3,194 | 1,271 | -4,407 | 2,969 | -3,812 | Upgrade
|
Change in Accounts Payable | 526.47 | -877.61 | 2,997 | -389.71 | -455.66 | Upgrade
|
Change in Other Net Operating Assets | -4,115 | -2,954 | -4,194 | -3,234 | -6,355 | Upgrade
|
Operating Cash Flow | 35,643 | 38,860 | 28,999 | 40,617 | 33,627 | Upgrade
|
Operating Cash Flow Growth | -8.28% | 34.00% | -28.60% | 20.79% | -4.64% | Upgrade
|
Capital Expenditures | -15,801 | -21,280 | -8,621 | -11,850 | -5,360 | Upgrade
|
Sale of Property, Plant & Equipment | 58.04 | 22.53 | - | 41.66 | 26.81 | Upgrade
|
Investment in Securities | -56,883 | 3,235 | 8,635 | 283.86 | -5,595 | Upgrade
|
Other Investing Activities | 0 | 25 | 180 | 10 | -9 | Upgrade
|
Investing Cash Flow | -72,626 | -17,998 | 193.48 | -11,515 | -10,938 | Upgrade
|
Short-Term Debt Repaid | - | -2,500 | -200 | -1,000 | -1,300 | Upgrade
|
Long-Term Debt Repaid | -38.79 | -4,080 | -16,817 | -4,300 | -2,301 | Upgrade
|
Total Debt Repaid | -38.79 | -6,580 | -17,017 | -5,300 | -3,601 | Upgrade
|
Net Debt Issued (Repaid) | -38.79 | -6,580 | -17,017 | -5,300 | -3,601 | Upgrade
|
Repurchase of Common Stock | - | - | -3,418 | - | - | Upgrade
|
Dividends Paid | -4,329 | -3,752 | -2,108 | -2,108 | -2,108 | Upgrade
|
Financing Cash Flow | -4,368 | -10,332 | -22,543 | -7,408 | -5,709 | Upgrade
|
Foreign Exchange Rate Adjustments | 1,152 | 113.04 | 441.94 | 671.96 | -418.12 | Upgrade
|
Miscellaneous Cash Flow Adjustments | - | - | 0 | -0 | 0 | Upgrade
|
Net Cash Flow | -40,199 | 10,644 | 7,092 | 22,367 | 16,562 | Upgrade
|
Free Cash Flow | 19,841 | 17,580 | 20,378 | 28,767 | 28,267 | Upgrade
|
Free Cash Flow Growth | 12.86% | -13.73% | -29.16% | 1.77% | 57.40% | Upgrade
|
Free Cash Flow Margin | 9.72% | 8.97% | 11.06% | 16.78% | 17.02% | Upgrade
|
Free Cash Flow Per Share | 3374.18 | 2989.54 | 3405.28 | 4794.06 | 4711.52 | Upgrade
|
Cash Interest Paid | 1.81 | 52.47 | 582.23 | 451.55 | 596.73 | Upgrade
|
Cash Income Tax Paid | 8,028 | 8,656 | 8,869 | 3,247 | 8,022 | Upgrade
|
Levered Free Cash Flow | 12,013 | 13,570 | 17,249 | 25,715 | 23,070 | Upgrade
|
Unlevered Free Cash Flow | 12,014 | 13,603 | 17,620 | 26,009 | 23,456 | Upgrade
|
Change in Net Working Capital | 3,267 | -3,848 | 3,571 | -8,280 | 1,211 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.